Aquestive Therapeutics: Q4 & Full Year 2024 Financial Results and 2025 Objectives Update
Warren, N.J., March 05, 2025 – Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pioneering pharmaceutical company dedicated to creating medicines that significantly enhance patients’ lives through innovative science and delivery technologies, recently reported their financial results for the fourth quarter and the full year ended December 31, 2024. Additionally, the Company provided an update on the key objectives that were previously announced for the year 2025.
Financial Highlights
For the fourth quarter of 2024, Aquestive reported total revenue of $48.3 million, representing a 38% increase compared to the same period in the previous year. The net loss for the quarter was $12.5 million, a decrease of 21% compared to the same quarter in 2023. The Company’s cash, cash equivalents, and marketable securities balance as of December 31, 2024, was $138.3 million.
Full Year 2024 Financial Results
Total revenue for the full year 2024 was $156.3 million, representing a 34% increase compared to 2023. The net loss for the year was $48.1 million, a decrease of 13% compared to the previous year. The Company’s cash, cash equivalents, and marketable securities balance as of December 31, 2024, was $138.3 million.
2025 Objectives Update
Aquestive Therapeutics continues to make progress on its objectives for 2025. The Company anticipates the initiation of a Phase 3 clinical trial for its sublingual thin film formulation of buprenorphine in the first half of 2025. Additionally, Aquestive plans to submit a New Drug Application (NDA) for this product candidate to the U.S. Food and Drug Administration (FDA) by the end of the year. The Company also intends to initiate a Phase 2 clinical trial for its sublingual thin film formulation of lisdexamfetamine dimesylate in the second half of 2025.
Impact on Individuals
The progress made by Aquestive Therapeutics in the development of innovative drug delivery technologies could potentially benefit individuals suffering from various health conditions. For example, the sublingual thin film formulation of buprenorphine is designed to address the unmet medical need for effective, convenient, and discreet treatment options for opioid use disorder. Similarly, the sublingual thin film formulation of lisdexamfetamine dimesylate has the potential to improve the treatment of attention deficit hyperactivity disorder (ADHD) by offering a more convenient and effective delivery method compared to traditional oral medications.
Impact on the World
The advancements made by Aquestive Therapeutics in the field of pharmaceutical innovation could have a significant impact on the global healthcare landscape. By addressing unmet medical needs through the development of new drug delivery technologies, the Company could contribute to improved patient outcomes and potentially reduce the overall burden on healthcare systems. Furthermore, the convenience and effectiveness of these new treatments could lead to increased patient compliance, which is crucial for managing chronic conditions such as opioid use disorder and ADHD.
Conclusion
Aquestive Therapeutics’ financial results for the fourth quarter and full year 2024, along with the update on their 2025 objectives, demonstrate the Company’s commitment to advancing medicines that bring meaningful improvement to patients’ lives through innovative science and delivery technologies. As Aquestive continues to make progress on the development of its sublingual thin film formulations of buprenorphine and lisdexamfetamine dimesylate, individuals suffering from opioid use disorder and attention deficit hyperactivity disorder, respectively, could potentially benefit from these new, convenient, and effective treatment options. Furthermore, the global healthcare community stands to gain from these advancements, as improved patient outcomes and increased patient compliance could help reduce the overall burden on healthcare systems.
- Aquestive Therapeutics reported strong financial results for Q4 and full year 2024, with total revenue increasing by 34% and 38%, respectively, compared to the previous year.
- The Company plans to initiate a Phase 3 clinical trial for its sublingual thin film formulation of buprenorphine in H1 2025 and submit an NDA by the end of the year.
- A Phase 2 clinical trial for the sublingual thin film formulation of lisdexamfetamine dimesylate is anticipated to begin in H2 2025.
- The potential benefits of these new drug delivery technologies include improved patient outcomes, increased patient compliance, and reduced burden on healthcare systems.
